Proto Oncogene Proteins C Myc
Mostrando 1-12 de 33 artigos, teses e dissertações.
-
1. Análise de proteínas cuja expressão é controlada por miRNA e relacionada à progressão do adenocarcinoma de próstata por imuno-histoquimica em tissue microarray / Analysis of proteins whose expression is controlled by miRNA and related to the progression of prostate adenocarcinoma by immunohistochemistry on tissue microarray
Introdução: O Câncer de Próstata (CaP) é o tumor mais comum do homem e a segunda causa de óbito por câncer no Brasil. MicroRNA (miRNA) é uma classe de pequenos RNA regulatórios não codificantes de proteínas que tem papel fundamental no controle da expressão dos genes. São responsáveis pelo controle de processos fundamentais na célula e estão
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 24/10/2012
-
2. Molecular cloning and analysis of Myc modulator 1 (Mm-1) from Bufo gargarizans (Amphibia: Anura)
The protein of Myc modulator 1 (Mm-1) has been reported to repress the transcriptional activity of the proto-oncogene c-Myc in humans. Moreover, it was shown to be the subunit 5 of human prefoldin (PFD). So far, this gene and its homologs have been isolated and sequenced in many organisms, such as mammals and fish, but has not been sequenced for any amphibia
Zoologia (Curitiba). Publicado em: 2010-02
-
3. Burkitt lymphoma: clinicopathologic, immunohistochemical and association with Epstein-Barr virus (EBV) in adult and pediatric population in different geographical regions of Brazil / Linfoma de Burkitt: características clinicopatológicas, imunoistoquímicas e associação com o vírus de Epstein-Barr (EBV) em populações adulta e pediátrica em diferentes regiões geográficas no Brasil
Burkitt lymphoma (BL) is a high grade B cell lymphoma with a consistent translocation involving the proto-oncogene C-MYC. The association with the Epstein-Barr virus (EBV) varies depending on the clinicopathological form. This study aims to analyze the clinicopathologic, immunohistochemical features, including the expression of transcription factor MUM1/IRF4
Publicado em: 2008
-
4. A biologia molecular no prognóstico do carcinoma da tireóide
This overview examines some selected genetic mechanisms of cancer development. Strong evidence has been accumulated suggesting that alteration in either the struture or activity of proto-oncogene contributes to the development and for the maintenance of the malignant phenotype. Many factors are known to interfere with both normal and pathological controls of
Revista do Colégio Brasileiro de Cirurgiões. Publicado em: 2003-12
-
5. Human proto-oncogene N-myc encodes nuclear proteins that bind DNA.
N-myc is a gene whose amplification has been implicated in the genesis of several malignant human tumors. We have identified two proteins with molecular weights of 65,000 and 67,000 encoded by N-myc. The abundance of these proteins in tumor cells was consonant with the extent of amplification of N-myc. The two proteins apparently arose from the same mRNA, we
-
6. The protein encoded by the human proto-oncogene c-myc.
The proto-oncogene c-myc may play a role in controlling the growth and division of normal cells, and abnormalities of the gene have been implicated in the genesis of a substantial variety of human tumors. To facilitate further study of these issues, we developed antisera that permit the identification and isolation of the protein encoded by the human and oth
-
7. Post-transcriptional control of c-myc proto-oncogene expression by glucocorticoid hormones in human T lymphoblastic leukemic cells.
We have studied the regulation of the human c-myc proto-oncogene by glucocorticoid hormones in T lymphoblastic leukemic cells. A significant decrease (50%) of the steady state levels of c-myc mRNA was observed as early as 3 h after dexamethasone treatment of CEM-1.3 human lymphoma cells, reaching less than 5% values, with respect to untreated cells, 24 h aft
-
8. Molecular mechanisms of cancer.
Cancer is caused by specific DNA damage. Several common mechanisms that cause DNA damage result in specific malignant disorders: First, proto-oncogenes can be activated by translocations. For example, translocation of the c-myc proto-oncogene from chromosome 8 to one of the immunoglobulin loci on chromosomes 2, 14, or 22 results in Burkitt's lymphomas. Trans
-
9. Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis.
Polycomb (Pc) is involved in the stable and heritable repression of homeotic gene activity during Drosophila development. Here, we report the identification of a novel human Pc homolog, hPc2. This gene is more closely related to a Xenopus Pc homolog, XPc, than to a previously described human Pc homolog, CBX2 (hPc1). However, the hPc2 and CBX2/hPc1 proteins c
-
10. Intracellular association of the protein product of the c-myc oncogene with the TATA-binding protein.
The c-myc proto-oncogene encodes nuclear phosphoproteins that bind DNA in a sequence-specific fashion and appear to function as transcriptional activators. Here we demonstrate that a 40-kDa nuclear protein coimmunoprecipitated with c-Myc specifically when nuclear proteins, extracted from nuclei of exponentially growing murine B-lymphoma WEHI 231 cells by usi
-
11. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential.
vav, a novel human oncogene, was originally generated in vitro by replacement of its normal 5' coding sequences with sequences from pSV2neo DNA, cotransfected as a selectable marker (S. Katzav, D. Martin-Zanca, and M. Barbacid, EMBO J. 8:2283-2290, 1989). The vav proto-oncogene is normally expressed in cells of hematopoietic origin. To determine whether the
-
12. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
OBJECTIVE: A refinement of prognostic variables using traditional pathologic markers integrated with oncogene proteins, enzymes, and hormonal factors may enhance the ability to predict for recurrence or survival in patients with mammary carcinoma. Although various oncogenes and oncogene products have been identified in human breast carcinoma, their relations